VERICEL CORPORATION Proceeds from Maturities, Prepayments and Calls of Short-term Investments
VERICEL CORPORATION (VCEL) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $64.44 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2022-02-24
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2020-12-31 was $9.40M, a 20.34% decline year-over-year.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2020-09-30 was $6.33M, a 77.65% decline year-over-year.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2020-06-30 was $12.66M, a 32.99% decline year-over-year.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2020-03-31 was $20.14M, a 24.25% decline year-over-year.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for fiscal 2021 was $64.44M, a 32.79% increase from fiscal 2020.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for fiscal 2020 was $48.52M, a 43.30% decline from fiscal 2019.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for fiscal 2019 was $85.58M, a 3789.86% increase from fiscal 2018.
- VERICEL CORPORATION proceeds from maturities, prepayments and calls of short-term investments for fiscal 2018 was $2.20M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $64.44M 10-K · filed 2022-02-24 | |||
| 2020-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $15.73M derived: sum of 2 quarters · filed 2022-02-24 | $28.39M derived: sum of 3 quarters · filed 2022-02-24 | $48.52M 10-K · filed 2022-02-24 |
| 2020-09-30 | $6.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $18.99M derived: sum of 2 quarters · filed 2020-11-05 | $39.12M 10-Q · filed 2020-11-05 | $50.92M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $12.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $32.80M 10-Q · filed 2020-08-05 | $44.60M derived: sum of 3 quarters · filed 2022-02-24 | $72.90M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $20.14M 10-Q · filed 2020-05-11 | $31.93M derived: sum of 2 quarters · filed 2022-02-24 | $60.23M derived: sum of 3 quarters · filed 2022-02-24 | $79.13M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $40.10M derived: sum of 2 quarters · filed 2022-02-24 | $59.00M derived: sum of 3 quarters · filed 2022-02-24 | $85.58M 10-K · filed 2022-02-24 |
| 2019-09-30 | $28.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $47.20M derived: sum of 2 quarters · filed 2020-11-05 | $73.78M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $18.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $45.48M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $26.58M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $2.20M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |